Correlation between the efficacy of amrubicin and the previous chemotherapy regimen for relapsed small cell lung cancer

Kasajima,Masashi; Igawa,Satoshi; Ishihara,Mikiko; Otani,Sakiko; Takakura,Akira; Yokoba,Masanori; Kubota,Masaru; Sasaki,Jiichiro; Katagiri,Masato; Masuda,Noriyuki

doi:10.3892/ol.2017.5662

Correlation between the efficacy of amrubicin and the previous chemotherapy regimen for relapsed small cell lung cancer

Authors:
- Masashi Kasajima
- Satoshi Igawa
- Mikiko Ishihara
- Sakiko Otani
- Akira Takakura
- Masanori Yokoba
- Masaru Kubota
- Jiichiro Sasaki
- Masato Katagiri
- Noriyuki Masuda
View Affiliations

Affiliations: Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa 252‑0374, Japan, Kitasato University School of Allied Health Sciences, Sagamihara, Kanagawa 252‑0373, Japan, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Kanagawa 252‑0374, Japan
Published online on: February 1, 2017 https://doi.org/10.3892/ol.2017.5662
Pages: 1719-1724

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Amrubicin has been demonstrated to be beneficial in the treatment of patients with relapsed small cell lung cancer (SCLC). The aim of the present study was to evaluate whether there is a significant difference in the efficacy of amrubicin between patients with relapsed SCLC who were previously treated with a platinum agent in combination with a topoisomerase I inhibitor, and those patients previously treated with a platinum agent in combination with a topoisomerase II inhibitor. The medical records of patients with SCLC, who were diagnosed as having relapsed following treatment with a platinum‑based regimen and subsequently received amrubicin monotherapy, were retrospectively reviewed. Of a total of 48 patients with SCLC who were treated with amrubicin, the overall response rate, median progression‑free survival (PFS) time and median survival time (MST) were determined to be 31.3%, 7.1 and 17.0 months, respectively. The response rate, PFS time and MST did not differ significantly between the patients treated previously with a platinum agent in combination with irinotecan, a topoisomerase I inhibitor, (36.4%, 5.7 and 11.4 months, respectively) and those treated previously with a platinum agent in combination with etoposide, a topoisomerase II inhibitor (30.0%, 4.7 and 14.8 months, respectively). The results indicate that amrubicin may be effective as a second-line chemotherapeutic agent for patients with SCLC, irrespective of which platinum agent and topoisomerase inhibitor‑based chemotherapy regimen was previously administered.

View Figures

View References

1	Jackman DM and Johnson BE: Small-cell lung cancer. Lancet. 366:1385–1396. 2005. View Article : Google Scholar : PubMed/NCBI
2	Davies AM, Lara PN, Lau DH and Gandara DR: Treatment of extensive small cell lung cancer. Hematol Oncol Clin North Am. 18:373–385. 2004. View Article : Google Scholar : PubMed/NCBI
3	Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 346:85–91. 2002. View Article : Google Scholar : PubMed/NCBI
4	Schiller JH, Adak S, Cella D, DeVore RF III and Johnson DH: Topotecan versus observation after cisplatin plus etoposide in extensive stage small cell lung cancer: E7593-A phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 19:2114–2122. 2001.PubMed/NCBI
5	Stupp R, Monnerat C, Turrisi AT III, Perry MC and Leyvraz S: Small cell lung cancer: State of the art and future perspectives. Lung Cancer. 45:105–117. 2004. View Article : Google Scholar : PubMed/NCBI
6	Ishizumi K, Ohashi N and Tanno N: Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds. J Org Chem. 52:4477–4485. 1987. View Article : Google Scholar
7	Noda T, Watanabe T, Kohda A, Hosokawa S and Suzuki T: Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs. 16:121–128. 1998. View Article : Google Scholar : PubMed/NCBI
8	Nogami N, Kiura K, Takigawa N, Harita S, Chikamori K, Shibayama T, Tabata M, Hotta K, Shinkai T and Tanimoto M: A phase II trial of combination chemotherapy with topotecan and amrubicin in small cell lung cancer (SCLC). J Clin Oncol. 28:(Suppl). 70542010.
9	Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, Takanashi S, Inoue C, Inage M, Yokouchi H, et al: Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol. 26:5401–5406. 2008. View Article : Google Scholar : PubMed/NCBI
10	Kaira K, Sunaga N, Tomizawa Y, Yanagitani N, Shimizu K, Imai H, Utsugi M, Iwasaki Y, Iijima H, Tsurumaki H, et al: A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. Lung Cancer. 69:99–104. 2010. View Article : Google Scholar : PubMed/NCBI
11	Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, Okamoto H, Ogura T, Yokoyama A, Seki N, et al: Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol. 24:5448–5453. 2006. View Article : Google Scholar : PubMed/NCBI
12	Hasegawa Y, Takeda K and Kashii T: Clinical experience of amrubicin hydrochloride (Calsed) monotherapy in previously treated patients with small-cell lung cancer. Jpn J Lung Cancer. 45:811–815. 2005. View Article : Google Scholar
13	Hirose T, Shirai T, Kusukoto S, Sugiyama T, Yamaoka T, Okuda K, Ohmori T, Ohnishi T and Adachi M: Showa University School of Medicine, Tokyo, Japan: Phase II study of amrubicin and carboplatin in patients with the refractory or relapsed small cell lung cancer (SCLC). J Clin Oncol. 28:S152010.
14	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
15	Gupta RS, Gupta R, Eng B, Lock RB, Ross WE, Hertzberg RP, Caranfa MJ and Johnson RK: Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res. 48:6404–6410. 1988.PubMed/NCBI
16	Sugimoto Y, Tsukahara S, Oh-hara T, Isoe T and Tsuruo T: Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 50:6925–6930. 1990.PubMed/NCBI
17	Sugimoto Y, Tsukahara S, Oh-hara T, Liu LF and Tsuruo T: Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res. 50:7962–7965. 1990.PubMed/NCBI
18	Tan KB, Mattern MR, Eng WK, McCabe FL and Johnson RK: Nonproductive rearrangement of DNA topoisomerase I and II genes: Correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst. 81:1732–1735. 1989. View Article : Google Scholar : PubMed/NCBI
19	Murakami H, Yamamoto N, Shibata T, Takeda K, Ichinose Y, Ohe Y, Yamamoto N, Takeda Y, Kudoh S, Atagi S, et al: A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). Lung Cancer. 84:67–72. 2014. View Article : Google Scholar : PubMed/NCBI
20	Hirukawa I, Yokoyama T, Hirata A, Takata S, Ishii H and Takizawa H: A retrospective study of amrubicin treatment in patients with relapsed small-cell lung cancer. Jpn J Lung Cancer. 5:3812014.
21	Sudo J, Tsuzuki H, Takahashi S, Yamane Y, Kurimoto F and Sakai H: Second-line chemotherapy for relapsed small-cell lung cancer. Nihon Kokyuki Gakkai Zasshi. 3:2332014.